Carlo Boutton

Boutton holds an MSc and PhD from KU Leuven, researching protein behavior under high electromagnetic fields, and brings more than 20 years of antibody and biochemistry leadership. He joined Biotalys in May 2022 as Chief Scientific Officer, having previously served as Global Head of Innovation for Large Molecules Research at Sanofi and held scientific leadership roles at Ablynx (now Sanofi) and Tibotec (a Johnson and Johnson subsidiary). He assumed the interim CEO role following the departure of Kevin Helash.